Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Anus Neoplasms 1

Interventions

pembrolizumab 9Carboplatin 9Docetaxel 8Paclitaxel 6Nivolumab 6Cisplatin 5Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4osimertinib 3fludarabine 3aldesleukin 3Radiotherapy 3Pemetrexed 3Erlotinib Hydrochloride 3Cyclophosphamide 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2atezolizumab 2alpha-2'-deoxythioguanosine 2Taxes 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Crizotinib 2Bevacizumab 2vistusertib 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × prexasertib × Thoracic × Clear all
NCT01115790 2016-05-10

A Phase 1 Study in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
150 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡